Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

• Nicola Gökbuget,
• Gerhard Zugmaier,
• Matthias Klinger,
• Peter Kufer,
• Matthias Stelljes,
• Andreas Viardot,
• Heinz A. Horst,
• Svenja Neumann,
• Monika Brüggemann,
• Oliver G. Ottmann,
• Thomas Burmeister,
• Dorothea Wessiepe,
• Max S. Topp,
• Ralf Bargou

Affiliations

Nicola Gökbuget

Center of Internal Medicine, Goethe University, Frankfurt, Germany

Gerhard Zugmaier

Amgen Research (Munich) GmbH, Germany

Matthias Klinger

Amgen Research (Munich) GmbH, Germany

Peter Kufer

Amgen Research (Munich) GmbH, Germany

Matthias Stelljes

Medical Department A, University of Münster, Germany

Andreas Viardot

Department for Internal Medicine III, University Ulm, Germany

Heinz A. Horst

Medical Department II, Christian-Albrechts University, Kiel, Germany

Svenja Neumann

Medical Department II, Christian-Albrechts University, Kiel, Germany

Monika Brüggemann

Medical Department II, Christian-Albrechts University, Kiel, Germany

Oliver G. Ottmann

Department of Haematology, Cardiff University, Cardiff, UK

Thomas Burmeister

Department for Hematology and Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany

Dorothea Wessiepe

Metronomia Clinical Research GmbH, München, Germany

Max S. Topp

Department of Internal Medicine II, Universitätsklinikum, Würzburg, Germany

Ralf Bargou

Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Germany